California Cannabis Distributor Nabis Triples Capacity With New SoCal Fulfillment Center, Adds New Partnerships
News provided by
Share this article
Nabis, California s largest licensed cannabis distributor, announced today the opening of their new Southern California fulfillment center and new partnerships with a number of market leading brands.
The 20,000 square-foot facility in Los Angeles allows Nabis to store three times the amount of product as its previous facility location. The highly secure, climate-controlled distribution hub can facilitate up to 1,200 orders per week, a 300% increase from their former locale. The larger facility enables Nabis to onboard partner brands in a wide range of product categories and offer additional services, such as third-party product testing.
/PRNewswire/ Focus on Diabetes™, a multi-year eye health initiative with the American Diabetes Association® (ADA), VSP® Vision Care and Regeneron, will host.
/PRNewswire/ - The Supreme Cannabis Company, Inc. ("Supreme" or the "Company" or "we") (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), is pleased to announce that, at.
Share this article
Share this article
TEL AVIV, Israel, June 9, 2021 /PRNewswire/ Good news for those seeking environmentally conscious dietary habits by reducing consumption of animal protein but cannot shake the craving for real milk in a hot cup of coffee or resist indulging in a rich cheesecake. The Israeli start-up Imagindairy, Ltd., is milking new technology to leave the cow out of the dairy equation. The company is creating true milk proteins that are indistinguishable from the real thing via a natural process of precision fermentation.
Recreating Casein and Whey
Imagindairy Leads “No Cow , Guilt-Free Dairy Revolution
Imagindairy s proprietary technology recreates nature-identical, animal-free versions of whey and casein proteins that can be used to produce dairy analogs. They have the flavor and texture – and, importantly, the functionality and nutritional value – of their animal-based counterparts. This opens new opportunities to develop a full range of non-da
Share this article
Share this article
International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression
Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants
TORONTO, June 9, 2021 /PRNewswire/ - Braxia Scientific Corp. ( Braxia , or the Company ), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the Guidelines ) for the clinical use of rapi